ArticleFrontiers in oncology2026

Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines.

Janneke J T M Melis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.